基于智慧药学服务平台的PCCM咳喘医药联合门诊对慢阻肺患者药学服务干预效果分析

Analysis of the Efficacy of PCCM Cough & Wheeze Joint Outpatient by Physicians and Pharmacists on Pharmaceutical Care Intervention for COPD Patients Based on the Intelligent Pharmaceutical Care Platform

关键词:  智慧药学服务平台  咳喘医药联合门诊  慢性阻塞性肺疾病  临床药师

Key words:  Intelligent pharmaceutical care platform  Cough Wheeze Joint Outpatient  COPD  Clinical pharmacist

摘要:

目的 基于智慧药学服务平台探索PCCM咳喘医药联合门诊对慢性阻塞性肺疾病(COPD)患者药学服务干预的应用价值。方法 选取2021年7月至2022年6月于南通大学附属医院PCCM咳喘医药联合门诊就诊的COPD患者200例,按照随机数字法分为对照组100例和实验组100例。对照组患者接受常规用药指导和健康宣教。实验组在对照组的基础上成立以临床药师为主导的药学服务团队,基于智慧药学服务平台对COPD患者进行标准化、个性化管理,观察两组患者的治疗效果和生存质量差异。结果 实验组患者的第1秒用力呼气量占预计值的百分比(FEV1/%)和第1秒用力呼气量占用力肺活量的百分比(FEV1/FVC)显著高于对照组(P＜0.05),COPD患者自我评估评分表(CAT)评分显著低于对照组(P＜0.05)。实验组的Morisky用药依从性量表(MMAS-8)评分显著高于对照组(P＜0.05),实验组的装置使用错误率显著低于对照组(P＜0.05)。实验组的药物不良反应反生率显著低于对照组(P＜0.05)。实验组的6分钟步行试验(6MWT)结果显著高于对照组(P＜0.05),实验组的圣乔治呼吸问卷(SGRQ)权重评分低于对照组(P＜0.05)。结论 基于智慧药学服务平台探索的PCCM咳喘医药联合门诊的药学服务模式对COPD患者的管理可显著改善患者肺功能和治疗效果,提高患者用药依从性,减少药物不良反应,提升患者活动耐力和生存质量。

Abstract:

Objective To explore the application value of PCCM cough wheeze joint outpatient by physicians and pharmacists on pharmaceutical care intervention for COPD Patients based on the intelligent pharmaceutical care platform. Method A total of 200 COPD patients were selected from July 2021 to June 2022 in the PCCM cough wheeze joint outpatient by physicians and pharmacists of Affiliated Hospital of Nantong University, and divided into control group (100 cases) and experimental group (100 cases) according to random number method.The control group received routine medication guidance and health education.The experimental group established a clinical pharmacists-led pharmaceutical care team based on the intelligent pharmaceutical care platform,and standardized and personalized management was carried out for COPD patients.Treatment effect and quality of life were compared between the two groups.Result The percentage of forced expiratory volume in the first second to the expected value (FEV1/%) and the percentage of forced expiratory volume in the first second to forced lung capacity (FEV1/FVC) in the experimental group were significantly higher than those in the control group (P < 0.05).The COPD assessment test(CAT) score in the experimental group were significantly lower than those in the control group (P < 0.05).The 8-item Morisky medicationadherence scale(MMAS-8) score in the experimental group were significantly higher than those in the control group (P < 0.05).The error rate of device use and the rate of adverse drug reactions in the experimental group was significantly lower than those in the control group (P < 0.05). The 6-minute walking test(6MWT) results in the experimental group were significantly higher than those in the control group(P < 0.05). The St.George""s Respiratory Questionnaire (SGRQ) weight score in the experimental group was lower than those in the control group (P < 0.05).Conclusion The management of patients with COPD in PCCM cough & wheeze joint outpatient by physicians and pharmacists on pharmaceutical care intervention based on the intelligent pharmaceutical care platform can significantly improve the patients"" lung function and treatment effect, increase the patients"" medication compliance, reduce the adverse drug reactions, and enhance the patients"" activity endurance and quality of life.